Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

Abstract Introduction Belantamab mafodotin (BM) is a new anti-BCMA antibody–drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP). Methods We conducted an...

Full description

Bibliographic Details
Main Authors: Adrián Alegre, Gonzalo Benzo, Rafael Alonso, Joaquín Martínez-López, Ana Jimenez-Ubieto, Clara Cuéllar, Elham Askari, Elena Prieto, Concepción Aláez, Beatriz Aguado, Alberto Velasco, Isabel Krsnik, Ana Bocanegra, Laura Llorente, Cristina Muñoz-Linares, Ana Morales, Eugenio Giménez, Rebeca Iglesias, Carmen Martínez-Chamorro, Aránzazu Alonso, Carmen Jiménez-Montes, María J. Blanchard, Grupo GM-GM
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-12-01
Series:Oncology and Therapy
Subjects:
Triple-class relapsed and refractory multiple myeloma
Belantamab mafodotin
Real-world outcomes
Effectiveness
Safety
Online Access:https://doi.org/10.1007/s40487-022-00212-5

Internet

https://doi.org/10.1007/s40487-022-00212-5

Similar Items